Cutaneous and ocular manifestations of IBD

Annals of Gastroenterology

Volumn 19, Issue 2, 2006, Pages 181-183

  Karamanolis, Georgios P ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPLEGIC AGENT; CYCLOSPORIN; DAPSONE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; POTASSIUM IODIDE; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CROHN DISEASE; DEBRIDEMENT; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; EPISCLERITIS; ERYTHEMA NODOSUM; EYE DISEASE; EYE INFLAMMATION; HUMAN; IRITIS; PREVALENCE; PYODERMA GANGRENOSUM; SCLERITIS; SKIN DISEASE; ULCERATIVE COLITIS; UVEITIS; WOUND CARE;

EID: 34548527330     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Berstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population based study. Am J Gastroenterol 2001; 96: 1116-1122.
2. Greenstein A, Janowitz H, Sachar D. Extra-intestinal complications of Crohn's disease and ulcerative colitis. Medicine 1976; 55: 401-412.
3. Veloso FT, Carvahlo J, Margo F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 729 patients. J Clin Gastroenterol 1996; 23: 29-34.
4. Schorr-Lesnick B, Brandt LJ. Selected rheumatologic and dermatologic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988; 83: 216-223.
5. Orchard TR, Chua CN, Ahmand T, et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002; 123: 714-718.
6. Fleisher M, Rubin S, Levine A, et al. Infliximab in the treatment of steroid refractory erythema nodosum of IBD. Gastroenterology 2002; 122 (suppl 1): A618 (abstract).
7. Kaufman I, Caspi D, Yeshurun D, The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int 2005; 25: 406-410.
8. Marshall JK, Irvine EJ. Successful therapy of refractory erythema nodosum associated with Crohn's disease using potassium iodide. Can L Gastroenterol 1997; 11: 501-502.
9. Fukunaga K, Sawada F, Fukuda Y, et al. Extracorporeal monocyte granulocytapheresis was effective for a patient of erythema nodosum concomitant with ulcerative colitis. Therap Apher Dial 2003; 7: 122-126.
10. Goudet P, Dozois RR, Kelly KA, et al. Characteristics and evolution of extraintestinal manifestations associated with ulcerative colitis after proctocolectomy. Dig Surg 2001; 18: 51-55.
11. van Boodegraven, Pena AS. Treatment of extraintestinal manifestations in inflammatory bowel disease. Curr Treat Opt Gastroenterol 2003; 6: 201-212.
12. Friedman S, Marison J, Scherl E, et al. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001; 7: 1-7.
13. D'Inca R, Fagiuoli SC. Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine. Ann Inter Med 1998; 128: 783-784.
14. Jolles S, Niclasse S, Benson E. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol 1999; 140:564-565.
15. Baumgat DC, Wiedenmann B, Dignass A. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis. Inflamm Bowel Dis 2004; 10: 421-424.
16. Hohenleutner U, Mohr VD, Michael S, Landthaler M. Mycophenolate mofetil and cyclosporine treatment for recalcitrant pyoderma gangrenosum. Lancet 1997; 350: 1748.
17. Tan MH, Gordon M, Lebwohl O, et al. Improvement of pyoderma gangrenosum and psoriasis associated with Chrohn disease with anti-tumor necrosis factor a monoclonal antibody. Arch Dermatol 2001; 137; 930-933.
18. Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated Crohn disease: Effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 2002; 37: 1108-1110.
19. Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1821-1826.
20. Alam M, Grossman ME, Schneiderman PI, et al. Surgical management of pyoderma gangrenosum: Case report and review. Dermatol Surg 2000; 26: 1063-1066.
21. Gibson LE. Sweet syndrome. Mayo Clin Proc 2005; 80: 549.
22. Kemmett D, Hunter JA. Sweet's syndrome: a clinico-pathologic review of twenty-nine cases. J Am Acad Dermatol 1990; 23: 503-507.
23. Orchard T. Extraintestinal complications of inflammatory bowel disease. Curr Gastroenterol Rep 2003; 5: 512-517.
24. Mintz R, Feller ER, Barh RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 135-139.
25. Danese S, Semerano S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005; 11: 7227-7236.
26. Finkelstein W. Treatment of acute episcleritis associated with Crohn's disease with infliximab. Am J Gastroenterol 2002; 97: S152.
27. Leibowitz HM. The red eye. N Engl J Med 2000; 343: 345-351.
28. Korelitz BL, Coles RS. Uveitis (iritis) with ulcerative and granulomatous colitis. Gastroeterology 1976; 52: 78-82.
29. Freis W, Giofre MR, Catanoso M, Lo Gullo R. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am J Gastroenterol 2002; 97: 499-500.